Mallinckrodt plc Stock: price and insider trades · United States
1 insider bought €48.0M of shares over the last 90 days, the latest by GOLDENTREE ASSET MANAGEMENT LP, filed 16 Oct 2026.
Mallinckrodt plc: what insiders have been doing
This page follows insider dealings at Mallinckrodt plc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 24 October 2025 to 24 October 2026, the disclosure feed for Mallinckrodt plc logged 41 filings by 16 insiders.
Only purchases show up on the open market, 9 purchases in all worth €158.6M, filed by 2 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €37.0M from Goldentree Asset Management LP, disclosed on 6 October 2026. The buyers include 2 major shareholders.
For context, the typical company on the same exchange (median of 3,169 companies) published 24 filings over the same period, against 41 filings here. Over the whole record (from 2013), the tally stands at 132 purchases and 64 sales. The 10-K for the year ended 31 December 2025 shows 1.43 bn USD of revenue and -489.5 m USD of net income.
The last purchase on record was published on 16 October 2026, which is 24 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 137,000 shares@ US$90.00Ordinary SharesSEC:0001493152-26-047403:0Canonical exit: 12 Jan 2027 (T+90)
- 463,000 shares@ US$91.00100.0% of flowOrdinary SharesSEC:0001493152-26-045958:0Canonical exit: 23 Dec 2026 (T+90)
- 328 sharesOrdinary SharesSEC:0001104659-26-086326:0
- 571 sharesOrdinary SharesSEC:0001104659-26-086329:0
- 763 sharesOrdinary SharesSEC:0001104659-26-086328:0
- 2,685 sharesOrdinary SharesSEC:0001104659-26-084773:0
- 619 sharesOrdinary SharesSEC:0001104659-26-084773:1
- 4,882 sharesOrdinary SharesSEC:0001104659-26-070524:0
- 3,580 sharesOrdinary SharesSEC:0001104659-26-070525:0
- 619 sharesOrdinary SharesSEC:0001104659-26-070520:1
- 2,685 sharesOrdinary SharesSEC:0001104659-26-070520:0
- 4,882 sharesOrdinary SharesSEC:0001104659-26-070521:0
- 825 sharesOrdinary SharesSEC:0001104659-26-070525:1
- 1,523 sharesOrdinary SharesSEC:0001104659-26-048785:0
- 1,305 sharesOrdinary SharesSEC:0001104659-26-048781:0
- 1,137 sharesOrdinary SharesSEC:0001104659-26-048782:0
- 275,000 shares@ US$88.5019.2% of flowCommon StockSEC:0001193125-26-161818:0Canonical exit: 14 Jul 2026 (T+90)
- 410,000 shares@ US$90.5029.3% of flowCommon StockSEC:0001193125-26-161818:1Canonical exit: 16 Jul 2026 (T+90)
- 33,651 sharesOrdinary SharesSEC:0001493152-26-006443:0
- 250,000 shares@ US$92.2518.4% of flowCommon StockSEC:0001193125-26-009126:0Canonical exit: 7 Apr 2026 (T+90)
- 513 sharesOrdinary SharesSEC:0001104659-26-000779:1
- 854 sharesOrdinary SharesSEC:0001104659-26-000777:1
- 2,398 sharesOrdinary SharesSEC:0001104659-26-000781:1
- 1,073 sharesOrdinary SharesSEC:0001104659-26-000783:1
- 2,107 sharesOrdinary SharesSEC:0001104659-26-000784:1
25 of 866 declarations
About Mallinckrodt plc
Mallinckrodt plc is a specialty pharmaceutical company listed on the US NYSE/NASDAQ market, with operations tied to the United States and a corporate structure registered in Ireland. For international investors, it should be viewed as a healthcare name with a long industrial legacy, a focused product portfolio, and a recent history shaped as much by restructuring and litigation as by product development. The company traces its roots back more than 150 years and became an independent public company after its separation from Covidien in 2013. Since then, Mallinckrodt has gone through major financial resets, including emergence from Chapter 11 in 2022, which remains highly relevant to how the equity is assessed.
Operationally, Mallinckrodt develops, manufactures, markets, and distributes specialty pharmaceutical products designed for specific and often complex medical needs. Its portfolio has historically included therapies in pain management, autoimmune and inflammatory disease, intensive care, and nuclear imaging. The business has also emphasized specialty generics and mature products, with commentary around finished-dosage pharmaceuticals, controlled-substance APIs, and differentiated formulations. This gives the company a mix of branded and non-branded exposure, but also leaves it sensitive to pricing pressure, regulatory scrutiny, reimbursement dynamics, and product concentration risk.
Read moreShow less
In recent communications, Mallinckrodt has highlighted a global commercial and manufacturing footprint and a portfolio built around established franchises that continue to generate cash. The company has also pointed to its efforts to streamline operations, strengthen the balance sheet, and improve financial flexibility. Recent corporate developments have remained closely tied to legacy opioid-related liabilities and associated settlement obligations, which continue to affect investor sentiment and the company’s financial narrative. In other words, this is not a pure growth story; it is also a capital-structure and liability-management story.
From a market-position perspective, Mallinckrodt occupies a niche within specialty pharma rather than competing as a broad diversified big pharma group. Its competitive strengths tend to come from regulatory expertise, entrenched customer relationships, manufacturing know-how, and the ability to support products with complex supply chains or clinical use cases. At the same time, investors must weigh these strengths against a history of restructuring, legal overhangs, and portfolio transitions. Headquartered in Dublin, Ireland, while operating in the United States and internationally, Mallinckrodt remains a high-scrutiny healthcare company whose equity case depends on execution, balance-sheet discipline, and the durability of its core product franchises.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
